参考文献/References:
[1] Popa CC,Badiu CD,Andronache LF,et al.Differential diagnosis in esophageal cancer.Review on literature[J].Revista De Chimie Bucharest Original Edition,2019,70(1):331-335.
[2] Chen W,He LB,Zheng R, et al.An initial screening strategy based on epidemiologic information in esophageal cancer screening:A prospective evaluation in a community-based cancer screening cohort in rural China-science direct[J].Gastrointestinal Endoscopy,2021,93(1):110-118.
[3] 张宇琳,吴 涛,刘鸿翔,等.手术联合新辅助化疗对局部晚期食管癌患者的疗效及生存时间研究[J].肿瘤药学,2017,7(3):300-303.
[4] 颜 芳,应明真,陈龙佩,等.白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J].中国癌症杂志,2020,30(8):632-635.
[5] 姜雪滨,尹晓芹,单丹妮,等.生物免疫治疗联合化疗对食管癌患者血清指标及癌组织survivin蛋白的影响[J].河北医药,2019,41(6):877-880.
[6] 王英南,张风宾,张韶辰,等.帕博利珠单抗致食管癌患者甲状腺功能减退合并心肌损害1例报告[J].中国肿瘤生物治疗杂志,2020,27(9):1068-1069.
[7] Jong-Mu S,Lin S,Shah MA,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):A randomised,placebo-controlled,phase 3 study[J].Lancet(London,England),2021,398(10302):759-771.
[8] 中国抗癌协会食管癌专业委员会.食管癌规范化诊治指南[M].北京:中国协和医科大学出版社,2013:8-15.
[9] 袁 勇,陈龙奇.AJCC第八版食管癌分期系统更新解读[J].中华外科杂志,2017,55(2):109-113.
[10] 张 萍,艾 斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.
[11] 宋养荣,程 蒿,刘 佳,等.Ⅲ期食管癌新辅助化疗后行腔镜手术治疗临床研究[J].陕西医学杂志,2021,50(11):1358-1361.
[12] 王 旭,张 洁,陈宏宏.同步放化疗联合尼妥珠单抗治疗食管癌的疗效及预后因素分析[J].癌症进展,2020,18(17):1782-1785,1805.
[13] 张栓宝,张燕平,严宁娟.康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子及生活质量的影响[J].陕西中医,2019,40(11):1566-1569.
[14] 姚 威.白蛋白结合型紫杉醇联合奈达铂化疗治疗晚期、复发转移性宫颈癌近远期疗效及安全性[J].湖南师范大学学报:医学版,2017,14(1):84-88.
[15] 颜 芳,应明真,陈龙佩,等.白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J].中国癌症杂志,2020,30(8):632-635.
[16] Shah MA,Bennouna J,Lin S,et al.P-279 pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus:Phase 2 KEYNOTE-180 study[J].Journal of Clinical Oncology,2016,34(4suppl):189-192.
[17] 陈 婧,高玉华,马丹丹,等.帕博利珠单抗联合培美曲塞、顺铂在食管鳞癌术前新辅助化疗中的效果及对SCCA、CEA、PD-1/PD-L1的影响[J].解放军医药杂志,2021,33(7):23-27,31.
[18] 李 丛,张 欣,吴府容,等.食管癌术后放疗骨照射剂量与骨髓抑制相关性[J].肿瘤预防与治疗,2019,32(1):25-29.
[19] 姜雪滨,尹晓芹,单丹妮,等.生物免疫治疗联合化疗对食管癌患者血清指标及癌组织survivin蛋白的影响[J].河北医药,2019,41(6):877-880.
[20] 叶雄俊,刘 军,张一帆,等.帕博利珠单抗联合阿昔替尼治疗晚期肾细胞癌的初步疗效分析[J].肿瘤综合治疗电子杂志,2020,6(4):39-43.
[21] 蒋玉欢,何本超,郑志刚,等.改良Miccoli微创术联合术后DC-CIK治疗甲状腺癌疗效及对患者血清Gal-3、sIL-2R水平的影响[J].陕西医学杂志,2020,49(11):1417-1421.
相似文献/References:
[1]胡珊珊,宋 彦,罗玉明,等.食管内放射支架对中晚期食管癌患者吞咽困难疗效及预后影响[J].陕西医学杂志,2019,(1):83.
HU Shanshan,SONG Yan,LUO Yuming,et al.Effect of esophageal stent on dysphagia and prognosis in patients with advanced esophageal cancer[J].,2019,(7):83.
[2]魏晓华,郭俊霞.不同内镜技术在食管癌及癌前病变筛查中的应用价值研究*[J].陕西医学杂志,2019,(5):591.
WEI Xiaohua,GUO Junxia..Application value of different endoscopy techniques in the screening of esophageal cancer and precancerous lesions[J].,2019,(7):591.
[3]马显平,张海斌.叉头框转录因子M1和增殖细胞核抗原在食管癌组织中的表达及与放化疗预后相关性分析[J].陕西医学杂志,2021,50(9):1150.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.027]
MA Xianping,ZHANG Haibin.Expression of FOXM1 and PCNA in esophageal carcinoma and their correlation with prognosis of radiotherapy and chemotherapy[J].,2021,50(7):1150.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.027]
[4]何 芸,张卫卫,孔祥云.血清白细胞介素-6、肿瘤坏死因子-α、活性氧在食管癌术后并发心房颤动患者体内表达水平及检测意义[J].陕西医学杂志,2022,51(7):816.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.011]
HE Yun,ZHANG Weiwei,KONG Xiangyun.Expression level and significance of serum IL-6,TNF-α and reactive oxygen species in patients with atrial fibrillation after esophageal cancer surgery[J].,2022,51(7):816.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.011]
[5]周 敏,张艳霞,郭 楠,等.甲磺酸阿帕替尼对裸鼠食管癌的抗肿瘤作用及机制研究[J].陕西医学杂志,2023,52(12):1670.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.009]
ZHOU Min,ZHANG Yanxia,GUO Nan,et al.Antitumor effect and mechanism of apatinib mesylate on esophageal cancer in nude mice[J].,2023,52(7):1670.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.009]
[6]易三凤,屈银宗,龚承先,等.环状RNA GRIN2B通过调控微小RNA-135b对食管癌细胞增殖和侵袭的影响实验研究[J].陕西医学杂志,2024,(3):308.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.004]
YI Sanfeng,QU Yinzong,GONG Chengxian,et al.Effects of circular RNA GRIN2B on proliferation and invasion of esophageal cancer cells through regulation of microRNA-135b[J].,2024,(7):308.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.004]
[7]万传科,王晓霞,张彦青,等.川陈皮素对食管癌KYSE150细胞存活、侵袭和凋亡的影响及机制实验研究[J].陕西医学杂志,2024,(3):407.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.026]
WAN Chuanke,WANG Xiaoxia,ZHANG Yanqing,et al.Effects of nobiletin on survival,invasion and apoptosis of esophageal carcinoma KYSE150 cells and its mechanism[J].,2024,(7):407.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.026]
[8]张少锋,李丹青,杜 凡,等.食管癌术后重症肺炎患者血清肺表面活性物质相关蛋白质-D、高迁移率族蛋白B1和中性粒细胞与淋巴细胞比值水平变化及检测意义[J].陕西医学杂志,2024,(8):1114.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.024]
ZHANG Shaofeng,LI Danqing,DU Fan,et al.Changes and detection significance of serum pulmonary surfactant associated protein,high mobility group box 1 protein and neutrophil-to-lymphocyte ratioin patients with severe pneumonia after esophageal cancer surgery[J].,2024,(7):1114.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.024]
[9]符梦婕,张 剑,李秋忆,等.长链非编码RNA淋巴细胞白血病缺失基因2/微小RNA-30c-5p/丝裂原活化蛋白激酶1轴在食管癌细胞紫杉醇耐药中的作用机制实验研究[J].陕西医学杂志,2024,(9):1155.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.001]
FU Mengjie,ZHANG Jian,LI Qiuyi,et al.Mechanism of lncRNA DLEU2/miR-30c-5p/MAPK1 axis in paclitaxel resistance in esophageal cancer cells[J].,2024,(7):1155.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.001]
[10]王银燕,黄 翠,朱 艳,等.长链非编码RNA UBE2Q1-AS1对食管癌细胞增殖和迁移的调节作用及机制实验研究[J].陕西医学杂志,2024,(9):1172.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.004]
WANG Yinyan,HUANG Cui,ZHU Yan,et al.Regulatory effect and mechanism of lncRNA UBE2Q1-AS1 on proliferation and migration of esophageal cancer cells[J].,2024,(7):1172.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.004]